Request a Quote

Cyprotex Highlights - December 2020


Season’s Greetings from Cyprotex

2020 has been a challenging year for all, but for our last newsletter of the year we’d like to take the time to reflect on what we’ve managed to achieve, despite the difficulties!

Read on and click below to browse the highlights…

Read our newsletters

Read our blog

FDA Guidance Update

We started 2020 with the US FDA finalising the draft regulatory guidance for in vitro DDI studies. While very little changed between this update and the 2017 draft, there were still some things to watch out for, particularly for metabolism-mediated drug interactions and transporter inhibition studies.

The good news is that here at Cyprotex, we have done all the hard work for you by summarising the changes in our blog, and by updating our free ADME and DDI Guides. Read the blog to see our review on the FDA changes and download your free guides using the links below.

Read the FDA update

Download the guides

Plenty of Publications

Cyprotex have led and contributed towards many publications released this year, covering a variety of topics such as mitochondrial respiratory inhibition, a review on DILI risk assessment strategy, and an update from our parent company, Evotec, discussing the use of transcriptomics in predictive toxicology.

Click on the links below to read all about our latest research:

Ask us about our research

A Year for Webinars

With a total of 10 different webinars produced, we have really made it our mission this year to spread the word of science across the globe! We have made all of our webinars free to watch on demand, so why not catch up over the holidays?

Click on the links below to view the webinars:

In Vitro Approaches to Cosmetic Safety

Early Mitochondrial Screening in Drug Safety

A Focus on Drug Transporters Series

New Approaches in Toxicology Series

Latest News from our Parent Company, Evotec

Read the latest news from parent company, Evotec:

  • Evotec publishes DDup 10: Transforming Toxicology Prediction via PanOmics.
  • Evotec and Sartorius partner with Curexsys for scalable manufacturing of exosome-based therapeutics.
  • Evotec achieves key milestones in targeted protein degradation with Bristol-Myers Squibb.
  • Evotec & Alloy Therapeutics partner to expand Evotec's antibody discovery platform.

Read the press releases here

Read the press releases here
Season's Greetings from the Evotec Group
Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683

or fill out the form below:


Download file